Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794964 | 0.97 | HCRTR1 (0.44) | HCRTR1HCRTR2HTR2ALTA4HKDM4E | |
| SCHEMBL4793668 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2HTR2ALTA4HKDM4E | |
| SCHEMBL4777203 | 0.81 | HCRTR1 (0.54) | HCRTR1HCRTR2HTR2ALTA4HKDM4E | |
| SCHEMBL4778065 | 0.81 | HCRTR1 (0.45) | HCRTR1HCRTR2HTR2ALTA4HKDM4E | |
| SCHEMBL4795670 | 0.80 | HCRTR1 (0.43) | HCRTR1HCRTR2HTR2A | |
| SCHEMBL5068144 | 0.78 | HCRTR1 (0.52) | HCRTR1HCRTR2LTA4HKDM4ESMN1; SMN2 | |
| SCHEMBL4773029 | 0.78 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL5067299 | 0.76 | TUBB4A (0.47) | HCRTR1HCRTR2HTR2ASMN1; SMN2HRH3 | |
| SCHEMBL8256535 | 0.75 | HTR2A (0.42) | HCRTR1HCRTR2HTR2ALTA4HKDM4E | |
| SCHEMBL5067298 | 0.75 | HCRTR1 (0.47) | HCRTR1HCRTR2HTR2ALTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | claimed |
| EP-1871752-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | claimed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885HTR2A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.